SCHEMBL19411386

SCHEMBL19411386

Cc1ccc(OCc2cc(F)c(C(=O)OC(C)(C)C)cc2C2CC2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 5/20 0.49
▸ ESR1 P03372 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ RXRA P19793 7/20 0.39
▸ NR1H2 P55055 7/20 0.39
▸ NR1H3 Q13133 5/20 0.39
▸ PPARD Q03181 1/20 0.37
▸ RAB9A P51151 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ SCN3A Q9NY46 1/20 0.36
▸ MAOA P21397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15599062 0.87 SCN9A (0.60) SCN9ARXRANR1H2NR1H3
SCHEMBL19429995 0.85 SCN9A (0.67) SCN9AESR1TP53POLBAPEX1
SCHEMBL15599293 0.83 SCN9A (0.71) SCN9ARXRANR1H2NR1H3
SCHEMBL22912689 0.82 SCN9A (0.50) SCN9AESR1TP53POLBAPEX1
SCHEMBL19411416 0.80 SCN9A (0.50) SCN9ARXRANR1H2NR1H3
SCHEMBL21075309 0.80 SCN9A (0.44) SCN9A
SCHEMBL15599056 0.79 SCN9A (0.64) SCN9ARXRANR1H2NR1H3FFAR4
SCHEMBL15599202 0.79 SCN9A (0.43) SCN9A
SCHEMBL23677150 0.79 SCN9A (0.46) SCN9AESR1TP53POLBAPEX1
SCHEMBL19411411 0.79 SCN9A (0.57) SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11203572-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2021-12-21 — — US disclosed
US-11203572-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2021-12-21 — — US disclosed
EP-3854782-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2021-07-28 — — EP disclosed
EP-3854782-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2021-07-28 — — EP disclosed
US-20210155588-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-05-27 — — US disclosed
US-20210155588-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-05-27 — — US disclosed
EP-3436432-B1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-01-27 — — EP disclosed
EP-3436432-B1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-01-27 — — EP disclosed
US-10766858-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2020-09-08 — — US disclosed
US-10766858-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2020-09-08 — — US disclosed
US-20190112264-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-04-18 — — US disclosed
US-20190112264-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-04-18 — — US disclosed
EP-3436432-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF Genentech, Inc. (US) 2019-02-06 — — EP disclosed
WO-2017172802-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-10-05 — — WO disclosed
WO-2017172802-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210155588-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, RRM1 SCN9A 1549/4885ESR1 2262/4885TP53 3304/4885
US-11203572-B2 Substituted benzamides and methods of use thereof BRIX1, RDX, RRM1 SCN9A 1549/4885ESR1 2262/4885TP53 3304/4885
US-20190112264-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 SCN9A 1547/4885ESR1 2340/4885TP53 3317/4885
US-10766858-B2 Substituted benzamides and methods of use thereof BRIX1, RDX, SULT2A1 SCN9A 1547/4885ESR1 2340/4885TP53 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback